Role of antifungal susceptibility testing in patient management

Current Opinion in Infectious Diseases

Volumn 19, Issue 6, 2006, Pages 538-543

  Forrest, Graeme ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antifungal resistance; Candida; Echinocandins; Filamentous fungi; Posaconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ASPERGILLUS; CANDIDA; CANDIDIASIS; CROSS RESISTANCE; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; MOULD; MUCORMYCOSIS; MYCOSIS; NONHUMAN; REVIEW; TREATMENT FAILURE; YEAST;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 33750505426     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328010682c     Document Type: Review

References (49)

1. Rogers TR. Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 2006; 27 (Suppl 1):7-11. This is an excellent review and discussion on antifungal resistance and its impact on clinical practice in a clear and easy to read format.
2. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33:1692-1696.
3. Chandrasekar P. Selection criteria for antifungals: the right patients and the right reasons. Int J Antimicrob Agents 2006; 27 (Suppl 1):17-20.
4. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009-2015. As posaconazole is new antifungal agent and without defined breakpoints, this is the most complete dataset available on its activity against medically important fungi. The data are complex, but may help the physician determine if posaconazole may be beneficial for salvage therapy in patients who are failing therapy.
5. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24:235-247.
6. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2. 2nd edn. Wayne, PA: CLSI; 2002.
7. Pfaller MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6:929-943.
8. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982-989.
9. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi: Approved Standard M38-A. Wayne, PA: CLSI; 2002.
10. Clinical and Laboratory Standards Institute. Reference Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved guideline M44-A. Wayne, PA: CLSI; 2004.
11. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35:1073-1080.
12. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19:435-447. A major paper in the field of antifungal susceptibility testing and clinical outcomes. The authors reviewed the breakpoints of fluconazole against Candida spp. and compared success rates from large studies, demonstrating a strong relationship between MIC, fluconazole dose and outcomes.
13. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43:4434-4440. These authors show increasing fluconazole resistance and emergence of non-Candida albicans strains.
14. Capoor MR, Nair D, Deb M, et al. Emergence of nonalbicans Candida species and antifungal resistance in a tertiary care hospital. Jpn J Infect Dis 2005; 58:344-348.
15. Pfaller MA, Boyken L, Messer SA, et al. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol 2005; 43:5208-5213. This paper confirms the established breakpoints for voriconazole by disk-diffusion can reliably detect resistance.
16. Lopez-Oviedo E, Aller AI, Martin C, et al. Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method. Antimicrob Agents Chemother 2006; 50:1108-1111. This paper demonstrates that disk diffusion methodology is as reliable and accurate as broth micro-dilution for determining posaconazole susceptibility in flamentous fungi.
17. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44:819-826. Using a large database of organisms and standardized susceptibility testing, these authors were the first to demonstrate a clear correlation between the interpretive breakpoints for voriconazole based on pharmacodynamic parameters and clinical end of treatment outcomes. This is an important paper to link these parameters and may lead to increased usage of voriconazole susceptibility testing in hospitals with large amounts of azole resistance.
18. Panackal AA, Gribskov JL, Staab, et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44:1740-1743. One of several papers reporting cross-resistance between fluconazole and voriconazole. Although they were in a cancer center, the authors used restriction fragment length polymorphism to show that it was the same strains of C. glabrata developing this high-level resistance.
19. Magill SS, Shields C, Sears CL, et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44:529-535. Another paper showing cross-resistance between azole drugs, but here the authors showed decreased susceptibility with voriconazole. The concept of changing class when resistance develops is promoted.
20. Alexander BD, Schell WA, Miller JL, et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80:868-871. This paper clearly shows that once resistance develops to fluconazole it may affect the newer azoles including posaconzole.
21. Pina-Vaz C, Costa-de-Oliveira S, Rodrigues AG, Espinel-Ingroff A. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry. J Clin Microbiol 2005; 43:4674-4679.
22. Klevay M, Ebinger A, Diekema D, et al. Disk diffusion testing using Candida spp. colonies taken directly from CHROMagar Candida medium may decrease time required to obtain results. J Clin Microbiol 2005; 43:3497-3499.
23. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50:2058-2063. With increased echinocandin usage, one of several emerging papers defining the resistance mechanism in Candida spp. to echinocandins. The paper is complex, but clearly defines the FKS1 mutation as the cause of resistance.
24. Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004; 42:3475-3482.
25. Pfaller MA, Boyken L, Hollis, et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006; 44:760-763. This paper clearly shows that resistance to caspofungin is uncommon regardless of geography despite its widespread use over the last 5 years.
26. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49:767-769.
27. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005; 49:3616-3623. This paper demonstrates the difficulty in using susceptibility testing for echinocandins, especially when there is no correlation with clinical outcomes as shown here.
28. Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006; 44:324-326.
29. Pfaller MA, Boyken L, Hollis, et al. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43:5425-5427.
30. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42:753-757. The authors bring up an important point with using echinocandins for empiric antifungal therapy in cancer centers. Knowing the gaps in your antifungal coverage is important especially with which fungi have intrinsic resistance to your selected antifungal. This is a good example where the echinocandins have no Trichosporon spp. activity and the fungus then emerged through empiric micafungin therapy.
31. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006; 50:1287-1292. The authors present the major problem with antifungal susceptibility testing by showing that resistance testing for amphotericin B in yeast did not correlate with clinical outcomes.
32. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14:643-658.
33. Moore CB, Sayers N, Mosquera J, et al. Antifungal drug resistance in Aspergillus. J Infect 2000; 41:203-220.
34. Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 2005; 25:1174-1180. This paper describes the difficulty in antifungal susceptibility testing and filamentous fungi in both identifying patients and clinical outcomes. The authors describe the pitfalls of such an approach and that the patient risk factors are often the cause of therapeutic failure.
35. Alcazar-Fuoli L, Mellado E, Garcia-Effron, et al. Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother 2006; 50:453-460. A complex paper that goes into the biochemical reasons for azole resistance in A. fumigatus. The authors illustrate the mechanisms of resistance and how it may apply clinically.
36. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50:917-921.
37. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42:1726-1734.
38. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398-1403. An important paper with clinical outcomes for posaconazole use in treating invasive fusariosis. This offers a potent option to treat on often fatal infection. It isworth noting, however, that this is salvage study data and caution should always be employed.
39. Van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-e65. Another paper showing the exciting potential of posaconazole in treating invasive zygomycosis. The results are impressive again with an infection that often is fatal if inadequately treated.
40. Lass-Florl C, Rief A, Leitner S, et al. In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus. Antimicrob Agents Chemother 2005; 49:2539-2540.
41. Lass-Florl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131:201-207.
42. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12 052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20:121-136.
43. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43:215-222.
44. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-1571.
45. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8:344-358.
46. Kahn JN, Hsu MJ, Racine F, et al. Caspofungin susceptibility in Aspergillus and nonAspergillus molds: inhibition of glucan synthase and reduction of beta-D-1, 3 glucan levels inculture. Antimicrob Agents Chemother 2006; 50:2214-2216.
47. Zaas AK, Steinbach WJ. Micafungin: the US perspective. Expert Rev Anti Infect Ther 2005; 3:183-190.
48. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
49. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49:5157-5159. Combination antifungal therapies offer a lot of potential and although not a clinical study, in-vitro data suggest excellent responses with difficult mold infections.